(E) Sanofi said it could potentially treat COVID-19 patients with its anti-malarial drug Plaquenil after what it described as “promising” early test results.

Sanofi said it was ready to work with French health authorities “to confirm these results.”

The initial trial, on twenty-four patients with coronavirus, used Plaquenil, a hydroxychloroquine molecule, which has also been used for decades for the treatment of autoimmune diseases like lupus or rheumatoid arthritis.

Six days after the start of taking Plaquenil, the virus had disappeared in three-quarters of those treated, said Professor Didier Raoult, who is director of the Institut Hospitalo-Universitaire (IHU) de Marseille.

Following is the press release of Sanofi in the US: Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19

To learn more about the research from Professor Raoult at the IHU Méditerranée-Infection and his expertise in the hydroxychloroquine and azithromycin as a treatment of COVID-19 :

You can follow the work of the IHU de Marseilles on Twitter.

Note: The picture above is le vieux port de Marseilles.

Copyright © 2005-2020 by Serge-Paul Carrasco. All rights reserved.
Contact Us: asvinsider at gmail dot com